Currently, 70% of Pharmaceutical organisations outsource at least one PV activity. This level is expected to increase to 80% by 2012.

International Stem Cell Corporation (OTCBB: ISCO), http://www.internationalstemcell.com, announced today that the recent presentation entitled "Hepatocyte-like cells derived from patient-specific human parthenogenetic stem cells possess functions of mature human hepatocytes including P450 activity" has been identified as an "AASLD Presidential Poster of Distinction" in the Stem Cells session of The Liver Meeting, the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), in Boston, MA, one of the most prestigious annual medical and scientific conferences. The abstract of the presentation is published in the peer-reviewed supplement to Hepatology, volume 52, number 4 (SUPPL), Oct. 2010, pg 965A, the official journal of the AASLD.

ISCO's CEO Andrey Semechkin, Ph.D., said, "For our cell biologists to have received this award from the leading society in the U.S. focused on treating liver diseases, demonstrates the high caliber of research being carried out at ISCO, and that human parthenogenetic stem cells and their differentiated derivatives are becoming of greater interest to the medical research community as a potential source of therapeutically valuable cells."

ISCO also announced today the initiation of the first in a series of animal studies designed to demonstrate whether hepatocytes and their progenitors derived from the human parthenogenetic stem cells show any disease modifying activity in vivo.

Dr. Nikolay Turovets, ISCO's Director of Research and Therapeutic Development said, "ISCO's continued focus on therapeutic development is critical to show that hepatocytes derived from stem cells can reproduce missing liver function in a diseased organism. Our first series of experiments are designed to test the ability of our cells to engraft and survive in vivo. A second set of experiments will investigate the functional activity of successfully engrafted cells. Data from these studies will also be used to guide the development of future IND submissions."

In other research news, ISCO announced that a grant in which ISCO is a partner, was recently funded by the Qualified Therapeutic Discovery Project Grants Program created under the healthcare reform legislation enacted last March. The study is led by Paul H. Chen, M.D. to investigate healing after corneal surgery using ISCO's corneal epithelial cells developed by ISCO's wholly-owned subsidiary Lifeline Cell Technology. ISCO's cells, combined with a proprietary surgical device developed by Dr. Chen, may provide safer and better long term results than LASIK. By utilizing ISCO's human corneal cells, ISCO and Dr. Chen believe that cellular enhanced PRK could eventually replace LASIK for many of the hundreds of thousands of patients who require corrective eye surgery.

According to Dr. Chen, "This collaborative work with ISCO could lead to a safer and more effective treatment that hopefully will provide quicker visual recovery, less pain, and an improved refractive correction outcome."

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and is developing a line of cosmeceutical products via its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments and therapeutic applications, the potential benefits of collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as" could", "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, hepatocytes, liver disease

International Stem Cell Corporation
Jeffrey D. Janus
Sr. Vice President, Operations
1-760-940-6383
jjanus@intlstemcell.com
or
Nikolay Turovets, Ph.D.
Director of Research and Therapeutic Development
nturovets@intlstemcell.com

As best we can determine, Patrick Cox, who has been and continues to be a strong supporter of our company, was required yesterday by his publisher to cease coverage of our stock and issue a sell recommendation because he has an equity interest in a company with which we do business that could have been perceived as a conflict of interest. That has resulted in numerous negative comments on investor message boards that referred to the sell recommendation without giving the background or a full explanation. As a result, I felt it was important that we put the day's events into proper context. The following are what I believe to be the relevant excerpts from Patrick's article:

As you know, I've been a huge promoter of International Stem Cell Corp.'s (OTCBB: ISCO) parthenogenic stem cell technology. I've not only told you about the company, but I appeared on John Mauldin's podcast show with ISCO board chairman Ken Aldrich about six months ago. Aldrich and Mauldin subsequently became friends and found that their organizations were a perfect fit for marketing ISCO's cosmeceutical skin care product.

John Mauldin asked me to be a part of that organization. We looked hard at Agora Financial's policies as well as applicable SEC regulations and concluded that there would be no conflict of interest because the position gave me no direct interest in ISCO or its stock price....

My publisher, however, has grown increasingly uncomfortable with this arrangement. The reason is not that Agora Financial believes that there would be an actual conflict of interest. Rather, it is that it might be perceived as one by some, in particular SEC lawyers....

My publisher's trading policy's aim, however, is to keep me purely objective and disinterested. This policy is debatable, but I respect it. My only option, therefore, is to issue a sell order or face the wrath of a disappointed spouse.

You can probably guess what that means. I'm going to have to issue a sell order.

Obviously, we can't know for certain if these articles caused the price movement yesterday, but we believe they were a major factor. Moreover, the comments and the response of investors to them are beyond our control, but we do want to reassure all interested parties that there is no information of which we are aware to justify the price fluctuation that occurred yesterday.

I hope this will prove helpful.

Sincerely,

Ken Aldrich

Chairman

International Stem Cell Corporation Announces Completion of Its First Manufacturing Run of Lifeline Skin Care's Stem Cell-Based Skin Rejuvenation Products

International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today that its wholly-owned subsidiary, Lifeline Skin Care, Inc., in partnership with an experienced OTC drug licensed manufacturer of cosmetic products, successfully manufactured its first scaled-up lots of stem cell-based skin creams, confirming that these unique products can be made in larger batch quantities and continue to meet Lifeline's high quality standards. This marks an important milestone in proving that two new technologies, the derivation of human parthenogenetic stem cells, and the packaging and delivery of critical anti-aging ingredients, including those derived from stem cells, can be scaled-up into a level of production suitable to meet commercial levels of demand.

Lifeline Skin Care's product development scientists have combined human parthenogenetic stem cell technology with the latest discoveries in skin rejuvenation to create its unique day and night skin care creams. ISCO's scientists were the first to intentionally create human parthenogenetic stem cells from unfertilized human eggs, thus avoiding the ethical concerns of harming a viable human embryo. ISCO's therapeutic research team discovered that such cells had qualities that made them suitable for skin care products, thus leading to the formation of ISCO's wholly-owned subsidiary, Lifeline Skin Care. Valuable assistance from ISCO's other wholly-owned subsidiary, Lifeline Cell Technology, allowed the rapid transition and scale-up of a research-based discovery into a quality-controlled commercial product. Lifeline Cell Technology is staffed with experts in the manufacture and quality control of cell based products.

According to Dr. Ruslan Semechkin, CEO of Lifeline Skin Care, "Although it will be necessary to continue to develop new technologies to further scale-up the production of our new skin care products, this first successful manufacturing run proves that the team of ISCO's therapeutic research scientists, in combination with Lifeline Skin Care's product development expertise and Lifeline Cell Technology's manufacturing and quality control expertise, has the ability to quickly develop and commercialize new products using stem cell technologies."

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and is developing a line of cosmeceutical products via its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments, the potential benefits of collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, skin care

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
1-760-940-6383
kaldrich@intlstemcell.com
or
Lifeline Skin Care, Inc.
Ruslan Semechkin, Ph.D., President & CEO
Vice President, International Stem Cell Corporation
ras@intlstemcell.com

(HealthDay News) -- Injecting a therapeutic molecule into muscle appears to jump-start the production of a crucial protein that's missing in patients with Duchenne muscular dystrophy, British researchers report.

The treatment so far is only applicable to about 13 percent of people with the debilitating and ultimately fatal disease, but scientists are hopeful that similar molecules might expand the treatment to a wider range of patients.

Duchenne muscular dystrophy affects about one in 3,500 males, and involves a progressive wasting of muscle due to a genetic inability to produce the protein dystrophin, a key component of muscle structure. No treatments are available for the illness, and most of those affected die by age 30.

Recently, molecules called antisense oligonucleotides have shown some promise. These molecules work by "skipping over" portions of the defective gene that would otherwise block dystrophin production. Read more...

Heart health

International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, and a new firm to be formed by John Mauldin announced today the formation of a new joint marketing venture to launch a line of skin care products developed by ISCO's wholly owned subsidiary, Lifeline Skin Care, Inc. ('LSC'). Mauldin, a significant marketing talent, is president of Millennium Wave Investments and author of an economic letter that goes to over 1.5 million readers.

Lifeline Skin Care's products have been in active development for well over a year and involve a unique high-technology, patent pending formulation for skin rejuvenation crèmes, developed using ISCO's proprietary 'parthenogenetic' stem cells that do not require the use of fertilized embryos. The product was discovered during ISCO's therapeutic stem cell research that revealed the stem cell's potential applications in skin cell rejuvenation. Part of the discovery included developing a way to surround the proteins from the stem cells with a nanovesicle allowing for extended shelf life and enhanced delivery of the product to the skin. Independent third party testing indicates that the crèmes (one for day and one for nighttime application) have significant positive effects on the look and feel of the skin.

'This represents an amazing leap forward in the combination of a variety of cutting edge technologies to yield products that have the potential to find significant consumer acceptance. The anti-aging market is extremely large, and Lifeline Skin Care is offering something completely new and different. We are excited about the prospects,' said Kenneth Aldrich, Chairman of ISCO.

Because the LSC products involve a unique extract from living parthenogenetic stem cells, rather than 'off the shelf' ingredients used by most skin care products, it takes additional time to manufacture the products. Building inventory in advance of demand is critical to avoid disappointing customers.

ISCO and LSC believe the collaboration with Mauldin will provide a much broader potential customer base and a much lower market cost per customer than the alternative marketing programs previously considered. As a result, LSC has revised its previously announced marketing launch plans to be certain that it will have adequate product on hand to meet initial demand.

The initial product offering will be to ISCO's own database of investors and followers, originally set to launch October and now scheduled for November to coordinate with Mauldin's timetable. That will be followed with an offering to Mauldin's extensive subscription base and to a select market of other potential purchasers.

Only after these initial offerings have been completed, involving a total of over 1.5 million potential customers, will more broad scale product offerings be made. 'This will enable us to measure probable future demand, assure our loyal investors and Mauldin's subscribers and affiliates that they will be able to purchase all the products they require while allowing LSC to build an inventory of the unique stem cell extract that is at the heart of this new product,' said Dr. Ruslan Semechkin, CEO of Lifeline Skin Care.

'We are extraordinarily excited to be able to offer LSC's products to our loyal client base in a way that assures they will be able to obtain the product they want, plus monthly refills as required, in spite of the fact that LSC's products are unique and require time and care by many people to bring to market,' said John Mauldin, founder and Chairman of Millennium. 'This is a truly revolutionary approach to skin care. Early test results are very promising and I am excited to be associated with a company of the scientific reputation of International Stem Cell Corporation and their world-renowned staff.'

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and is developing a line of cosmeceutical products via its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments and therapeutic applications, the potential benefits of collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, skin care

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
1-760-940-6383
kaldrich@intlstemcell.com
or
Lifeine Skin Care, Inc.
Ruslan Semechkin, Ph.D., President & CEO
Vice President, ISCO
ras@intlstemcell.com

(HealthDay News) -- People with type 1 diabetes don't need to worry that they may have brain function problems in the future if they've had a bout or two of severe hypoglycemia (low blood sugar), a new study suggests.

Researchers found that while serious hypoglycemic episodes did sometimes occur as a result of aggressive diabetes control, those low blood sugar events didn't have any effect on cognitive function.

"Hypoglycemia did not seem to predict the advent of worsening cognitive function," said the study's lead author, Dr. Alan Jacobson, director of the behavioral and mental health research program at the Joslin Diabetes Center in Boston.

"Of course, it goes without saying that hypoglycemia can be a serious problem," he added. "But, if you've had a more severe hypoglycemia event, at least it appears that you don't have to worry that 10 years later you may have trouble doing your job or thinking," he said.

Results of the study were published in the May 3 New England Journal of Medicine. Read more...

Detox cleansing

When Jim Laidler’s oldest son, Benjamin, was diagnosed with autism, he and his wife started looking for help. “The neurologists were saying, ‘We don’t know what causes autism, and we don’t know what the outcome for your son will be,’” Laidler relates. “No one was saying, ‘Here’s what causes it; here’s what treats it.’”

But when the Laidlers, who live in Portland, Ore., searched the Web, they found dozens of “biomedical” treatments that promised to improve or even cure Benjamin’s inability to talk, interact socially or control his movements. So the parents tried them on their son. They began with vitamin B6 and magnesium, the nutritional supplements dimethylglycine and tri­methylglycine, vitamin A, gluten- and casein-free diets, the digestive hormone secretin, and chelation, a drug therapy de­signed to purge the body of lead and mercury. They applied the purported treatments to Benjamin’s little brother, David, who also was diagnosed with autism. Chelation did not seem to help much. Any effect from secretin was hard to tell. The diets showed promise; the Laidlers hauled special food with them everywhere. And Mom and Dad continued to feed the boys dozens of supplements, calibrating doses up and down with every change in behavior.

[More]

(HealthDay News) -- An intensive lifestyle change program helped people with type 2 diabetes lose weight and keep it off, a new study shows.

The program also led to improved control of blood glucose levels and reduced risk factors for cardiovascular disease, both of which are critical in preventing long-term complications caused by diabetes.

The study included 5,145 overweight or obese people, average age 58.7, with type 2 diabetes. About half were assigned to a lifestyle intervention that included diet changes and physical activity designed to achieve a 7 percent weight loss in the first year and maintain it in subsequent years.

The other participants were assigned to a diabetes education and support group that held three sessions a year to discuss diet, exercise and social support.

After four years, the participants in the lifestyle intervention group had lost an average of 6.2 percent of their body weight, compared with 0.9 percent for the diabetes support group. The lifestyle intervention group also had greater improvements in fitness, blood glucose control, blood pressure and levels of "good" HDL cholesterol. Read more...

Detox and cleanse

(HealthDay News) -- Researchers report that germs living in your gut could affect your risk of developing colon cancer.

The findings suggest that signs of the existence of some germs "are more frequently detected in subjects with polyps, early lesions that can develop into cancer, while other bacterial signatures are less frequently observed in such individuals," Tyler Culpepper, a University of Florida researcher, said in a news release.

Culpepper and colleagues studied 91 patients and took biopsy samples from their colons. They analyzed the bacteria in 30 people who had at least one polyp and 30 people who didn't but were of similar age and gender.

Researchers found some bacterial signatures only in those who had polyps and others only in those who didn't. Others were more common in one group or the other.

The findings suggest that future screening tests could aim to detect signs of trouble in the colon by measuring bacteria levels, Culpepper said. Read more...

Detox the body

(NaturalNews) Many herbal remedies are used to treat symptoms of diabetes and have shown results in naturally lowering blood sugar levels. Scientific research is now shedding new light on the mechanisms used since ancient times to treat diabetes with herbs and nutrition.

Diabetes was noted as far back as Ancient Greece. The name comes from two Greek words meaning the siphon and to run through, which describes the diabetic symptom of excess urine. Diabetes is one of the leading causes of death in the United States, where over twenty three million, almost eight percent of the population, have been diagnosed with the disorder. The number of cases of diabetes doubled from 1990 to 2005 and is expected to double again by 2050. Side effects of diabetes include kidney disease, congestive heart failure, stroke, blindness and hearing loss.

The cause of diabetes is not known but 90% of those with Type 2 diabetes are obese. Most consider that diabetes is triggered by numerous factors, including inheritance, nutrition, obesity, infection, hormonal imbalances, and stress. Read more...

Healthy blood

(HealthDay News) -- Positive brain changes take hold after just 11 hours of practicing a form of meditation, the results of a new study suggest.

The study included 45 University of Oregon students who were randomly selected to be in either a study group that did integrative body-mind training (IBMT) or a control group that did relaxation training. IBMT was adapted from traditional Chinese medicine in the 1990s.

A comparison of scans taken of the students' brains before and after the training showed that those in the IBMT group had increased brain connectivity. The changes were strongest in connections involving the anterior cingulate, an area that plays a role in the regulation of emotions and behavior, Yi-Yuan Tang of Dalian University of Technology in China, University of Oregon psychologist Michael I. Posner, and colleagues found.

The boost in brain connectivity began after six hours of IBMT and became more apparent after 11 hours of practice, according to the report published in the Aug. 16-21 online edition of the Proceedings of the National Academy of Sciences. Read more...

Memory concentration, loss of memory

This article has some useful information but, of course, cannot openly tell their readers that this is truly valuable so they have to attack it somehow. If you are not taking ACS 200 yourself, maybe you do not believe that it has germ killing powers?

I believe that infections are part of our current health crisis! I believe that it is well proven that we have organisms in the mouth that are difficult to identify and dangerous when they make their way into the systemic circulation, which they ALWAYS manage to do. I hold my ACS 200 in the mouth at least a minute 2-3 times a day. I think that lowering my total body burden of infections is just as useful for optimizing my health as lowering my burden of other toxins, like heavy metals.

Your patients may be confused by this article so take a moment to see it lacks clarity and even contradicts itself. Read more...

Lose weight quick

Meat allergies may be much more common than previously thought and may even induce potentially fatal anaphylaxis in some people, according to a study conducted by researchers from the University of Virginia and presented at the annual meeting of the American Academy of Allergy, Asthma and Immunology in New Orleans.

The researchers tested three groups of people across the U.S. Southeast with a history of recurrent anaphylaxis without known cause for an immune reaction to alpha-gal, a kind of sugar found in mammal meat.

Although most allergic reactions are caused by proteins, scientists recently discovered that alpha-gal is responsible for anaphylactic reactions to cetuximab, a cancer drug. Further studies revealed that people who experience immune responses to alpha-gal also develop allergic symptoms within three to six hours of eating mammalian meat.

Alpha-gal is not found in the flesh of bird or fish.

The researchers found that between 20 and 50 percent of participants tested positive for allergy to alpha-gal. Overall, 25 of 60 participants (42 percent) showed signs of meat allergy. Read more...

Female Sexual health